Women's Health. 2007;3(4):395-408. In two large, randomized, multicenter studies, which compared drospirenone/ethinyl estradiol 30 µg with desogestrel 150 µg/ethinyl estradiol 30 µg, there were no ...

Credit: Getty Images. The approval was based on data from two phase 3 studies that evaluated the safety, acceptability, efficacy, and cycle control of Nextstellis in 3725 women aged 16 to 50.

Safyral is engineered to reduce the risks of rare neural tube defects. Combination oral contraceptives reduce the risk of pregnancy primarily by inhibiting ovulation. This product combines ...

Please provide your email address to receive an email when new articles are posted on . Pregnancy rates were 0.09% when women reported taking all hormone pills vs. 1.6% when women reported missing ...

Credit: Getty Images. Nextstellis is a novel combined oral contraceptive pill containing drospirenone 3mg (DRSP) and estetrol 14.2mg. The Food and Drug Administration (FDA) has approved Nextstellis ® ...

The novel combined oral contraceptive pill includes estetrol 15mg (E4) and drospirenone 3mg (DRSP). The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for E4 ...

The Food and Drug Administration has announced a recall of Drospirenone and Ethinyl Estradiol tablets that may have missing or incorrect tablet arrangement. That's birth control, and the announcement ...

Labels for oral contraceptives that contain drospirenone will now note that studies have shown as much as a threefold increase in risk of blood clots compared with other birth control pills, the FDA ...

The ethinyl estradiol and drospirenone information that follows was obtained from studies of the combination ethinyl estradiol 20 µg/drospirenone 3 mg 24/4 formulation. The ethinyl estradiol in single ...